These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37535994)

  • 1. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
    McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
    Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
    Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
    Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer.
    Nelson OL; Rosales R; Turbov JM; Thaete LG; Cline JM; Rodriguez GC
    Cancer Prev Res (Phila); 2022 Feb; 15(2):75-86. PubMed ID: 34844992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
    Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
    Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
    Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
    Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
    Feng L; Yang W; Zhao H; Bakkum-Gamez J; Sherman ME; Kannan N
    Methods Mol Biol; 2022; 2429():445-454. PubMed ID: 35507180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors.
    Grimley E; Cole AJ; Luong TT; McGonigal SC; Sinno S; Yang D; Bernstein KA; Buckanovich RJ
    Theranostics; 2021; 11(8):3540-3551. PubMed ID: 33664846
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond
    Samuel D; Diaz-Barbe A; Pinto A; Schlumbrecht M; George S
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
    Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
    Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.
    Shaw PA; Rouzbahman M; Pizer ES; Pintilie M; Begley H
    Mod Pathol; 2009 Sep; 22(9):1133-8. PubMed ID: 19543244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.
    Zhang S; Dolgalev I; Zhang T; Ran H; Levine DA; Neel BG
    Nat Commun; 2019 Nov; 10(1):5367. PubMed ID: 31772167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.